CLYM MEXC RealStocks
Own real CLYM shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 22:05:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Climb Bio, Inc. (CLYM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.86, with a market capitalization of $689.59M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.64 to $18.33. This page covers its latest market performance, valuation, price trends and company information.
$689.59M | |
$11.97 | |
$12.80 | |
$10.68 | |
$12.25 | |
1.23M | |
1.45M | |
-- | |
$18.33 | |
$1.64 | |
-- | |
-- |
Climb Bio, Inc. (CLYM) is trading at $10.81 in after-hours trading as of 2026-11-12 21:38:00, down 0.49% ($0.05) from the regular-session close of $10.86.
After-hours trading shows how investors are pricing CLYM after the regular session closes. The current after-hours price is near the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Climb Bio, Inc. (CLYM) moved from $9.75 to $10.86, representing a gain of 11.42% ($1.11).
The stock traded between $8.49 and $12.80 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 1.36 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55.3%
CLYM is currently trading at $10.86, placing it 55.3% of the way from its 52-week low of $1.64 to its 52-week high of $18.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Climb Bio, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Climb Bio, Inc. (CLYM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CLYM, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CLYM shares and USD.
CLYM Shares to USD
1.00 CLYM shares = 10.863 USD
Calculations are estimates based on the latest available price and are for reference only.